Drugs / Milrinone
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02077010 | Jun 2020 → Jan 2023 | cardiomyopathy, heart failure | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01571037 | Apr 2012 → Feb 2013 | advanced heart failure | University of Nebraska | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01956006 | Oct 2013 → May 2017 | heart failure | The Alfred | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary | ||||||
| Phase 2 | NCT05122884 | Dec 2021 → Dec 2024 | infectious disease with sepsis | Mahidol University | Unknown | Met primary |
| Phase 2 | NCT04282629 | Jul 2021 → Jul 2025 overdue | acquired aneurysmal subarachnoid hemorrhage | University Hospital, Toulouse | Recruiting | No outcome recorded |
| Phase 2 | NCT02951130 | Oct 2017 → Sep 2024 | congenital diaphragmatic hernia, pulmonary hypertension, neonatal, pulmonary hypoplasia, respiratory failure | NICHD Neonatal Research Network | Completed | No outcome recorded |
| Phase 2 | NCT01841177 | Apr 2013 → Aug 2020 | congenital heart disease | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 2 | NCT01725776 | Dec 2006 → Feb 2012 | pulmonary hypertension | Montreal Heart Institute | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT04362527 | Aug 2020 → Oct 2025 | intracranial vasospasm | University Hospital, Angers | Completed | No outcome recorded |
| Phase 3 | NCT03823781 | Feb 2019 → Jan 2021 | — | Shanghai Children's Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00446017 | Jun 2003 → Aug 2004 | heart failure | University of Luebeck | Completed | No outcome recorded |
| Phase 3 | NCT01621971 | Jan 2003 → Jan 2004 | mitral valve insufficiency, pulmonary hypertension | Konkuk University Medical Center | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT06562036 | Dec 2023 → May 2024 | pulmonary hypertension, neonatal | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT02549066 | Jan 2016 → Jun 2017 | impaired renal function disease | Sahlgrenska University Hospital | Completed | No outcome recorded |
| — | NCT02408003 | Mar 2014 → May 2016 | aortic valve stenosis, diastolic heart failure | Sahlgrenska University Hospital | Completed | No outcome recorded |
| — | NCT01088997 | Jun 2010 → Feb 2013 | persistent fetal circulation syndrome | Children's Hospital of Philadelphia | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00695929 | Jul 2008 → Sep 2009 | cardiogenic shock, congenital heart disease | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | No outcome recorded |
| Comparator or background therapy34 trials | ||||||
| Phase 0 | NCT05700617 Comparator | Jul 2023 → Jun 2026 overdue | cardiogenic shock, heart failure | University of Chicago | Recruiting | No outcome recorded |
| Phase 1 | NCT04391478 Comparator | Jan → Apr 2015 | pulmonary hypertension, neonatal | Rania Ali El-Farrash | Completed | No outcome recorded |
| Phase 1/2 | NCT03180450 Background | Dec 2025 → Jun 2026 | heart failure | Sclnow Biotechnology Co., Ltd. | Suspended | No outcome recorded |
| Phase 1/2 | NCT02595541 Comparator | Jun → Oct 2015 | pulmonary hypertension | Assiut University | Completed | No outcome recorded |
| Phase 1/2 | NCT01849094 Comparator | May 2013 → Dec 2014 | heart failure | The Alfred | Completed | No outcome recorded |
| Phase 1/2 | NCT01576094 Comparator | Nov 2009 → Nov 2010 | — | Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz | Completed | No outcome recorded |
| Phase 2 | NCT05450328 Comparator | Dec 2025 → May 2028 expected | heart failure, postoperative ventricular dysfunction | Montreal Heart Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT05131867 Comparator | Nov 2021 → May 2022 | intracranial vasospasm | Zagazig University | Completed | No outcome recorded |
| Phase 2 | NCT02712788 Comparator | Apr 2016 → Oct 2017 | intracranial vasospasm | Indiana University | Terminated | No outcome recorded |
| Phase 2 | NCT02644057 Comparator | Mar → Sep 2016 | cardio-renal syndrome | Maimonides Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02098629 Comparator | May 2015 → Mar 2023 | myocardial infarction | Shantou University Medical College | Completed | No outcome recorded |
| Phase 2 | NCT02232399 Comparator | Oct 2014 → Apr 2017 | congenital heart defects, multiple types | Göteborg University | Completed | Missed primary |
| Phase 2 | NCT01301313 Comparator | Feb 2011 → Feb 2012 | heart failure | Jose Luis Vazquez Martinez | Terminated | No outcome recorded |
| Phase 2 | NCT00819377 Comparator | Feb 2009 → Jan 2012 | coronary artery disorder, heart valve disorder, pulmonary hypertension | Andre Denault | Completed | No outcome recorded |
| Phase 2 | NCT00543309 Comparator | Oct 2007 → Jan 2013 | congenital heart disease | John M Costello | Terminated | Missed primary |
| Phase 2 | NCT00549107 Comparator | Sep 2007 → ? | — | Ludwig Boltzmann Gesellschaft | Unknown | No outcome recorded |
| Phase 2 | NCT00338455 Background | Sep 2006 → Oct 2007 | congestive heart failure, impaired renal function disease, kidney failure | Scios, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT05838846 Comparator | Apr 2023 → Jan 2025 | pulmonary hypertension | Menoufia University | Completed | No outcome recorded |
| Phase 3 | NCT06679855 Comparator | Jun 2025 → Jun 2027 expected | — | NICHD Neonatal Research Network | Recruiting | No outcome recorded |
| Phase 3 | NCT06301880 Comparator | Jan 2022 → Jan 2023 | — | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT04484675 Comparator | May 2023 → May 2025 overdue | pulmonary hypertension | Zagazig University | Recruiting | No outcome recorded |
| Phase 4 | NCT07186062 Comparator | Jun 2022 → Jun 2024 | cardio-renal syndrome | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT05267886 Comparator | Mar 2022 → Dec 2026 expected | cardiogenic shock | Ottawa Heart Institute Research Corporation | Recruiting | No outcome recorded |
| Phase 4 | NCT05132153 Comparator | Oct 2021 → Sep 2022 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT03855579 Comparator | Mar → Sep 2019 | — | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT03207165 Comparator | Aug 2017 → Jun 2020 | acute coronary syndrome, cardiogenic shock, pulmonary edema | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02640846 Comparator | Dec 2015 → Jan 2019 | cardiomyopathy, infectious disease with sepsis | Sahlgrenska University Hospital | Unknown | No outcome recorded |
| — | NCT07144267 Comparator | Mar 2026 → Dec 2027 expected | — | Mansoura University | Not yet recruiting | No outcome recorded |
| — | NCT05064202 Background | Oct 2023 → Oct 2027 expected | cardiogenic shock | Amsterdam UMC, location VUmc | Not yet recruiting | No outcome recorded |
| — | NCT04792424 Background | Apr 2021 → May 2022 | — | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT04718350 Comparator | Jan 2021 → Dec 2023 | heart failure, pulmonary hypertension | Aretaieion University Hospital | Completed | No outcome recorded |
| — | NCT02726620 Background | Jan → Dec 2017 | hypotensive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT02730117 Background | Mar 2016 → Jul 2017 | acute kidney injury | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT00966745 Comparator | Jan → Dec 2008 | — | Seoul National University Hospital | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 53 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Milrinone | “milrinone (Baxter Pharmaceuticals, Ahmedabad, India) 10 mg in 20 ml of dextrose 5%, nitroglycerin (Caspian Tamin Pharmaceutical, Guilan, Iran) 10 mg in 20 ml of normal saline,...” NCT06301880 ↗50“including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.” NCT03180450 ↗ “Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine” NCT04792424 ↗ “Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine” NCT02730117 ↗ “dopamine and / or dobutamine and / or milrinone and / or adrenaline” NCT01301313 ↗ “Enoximone, Dobutamine, Dopamine, Milrinone” NCT05064202 ↗ |
| Known as | Milrila | ChEMBL registry synonym — accepted as the source's own label CHEMBL189 ↗ |
| Known as | Milrinona | ChEMBL registry synonym — accepted as the source's own label CHEMBL189 ↗ |
| Known as | milrinone lactate | “milrinone lactate, 1mg/ml, for intra venous use only” NCT04391478 ↗ |
| Known as | NSC-760072 | ChEMBL registry synonym — accepted as the source's own label CHEMBL189 ↗ |
| Known as | Primacor | ChEMBL registry synonym — accepted as the source's own label CHEMBL189 ↗ |
| Known as | WIN 47,203-2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL189 ↗ |
| Action | Inhibit | “This suggests that the use of adrenaline for the treatment of postoperative myocardial dysfunction - in contrast to treatment with the PDE-III inhibitor milrinone - is...” PMID 17470271 ↗ 20071“Phosphodiesterase 3A inhibitor” CHEMBL189 ↗ |
| Modality | Small molecule | — CHEMBL189 ↗ |
| Route | Intravenous | “continuous intravenous infusion of dobutamine or milrinone” NCT00338455 ↗ |
| Target | PDE3A | “Phosphodiesterase 3A inhibitor” CHEMBL189 ↗ |